Tesamorelin in Las Vegas

Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog that has been studied, including in FDA-reviewed contexts, for the reduction of visceral adipose tissue. It signals the body's own growth hormone pathways.

Tesamorelin requires a medical evaluation first. Dr. Charles Kamen, MD uses your labs and goals to decide whether a protocol is appropriate and supervises it if prescribed.

On the evidence, tesamorelin has the strongest regulatory pedigree of these growth-hormone peptides: it is FDA-approved as Egrifta, and the landmark trial (Falutz, N Engl J Med, 2007) showed it reducing visceral adipose tissue in adults with HIV-associated lipodystrophy. That approval is for a specific condition and a specific population, though - it is not a general "belly fat" medication, and it is not FDA-approved for the broader longevity or body-composition goals people sometimes pursue. Used outside that indication, it is physician-supervised and off-label.

Who it is considered for: typically individuals who want an honest, evidence-informed review of whether a GHRH analog fits their labs, goals, and history. It is not a weight-loss shortcut, it is not appropriate for everyone, and it is not a substitute for proven metabolic care. Candidacy, and any caution or contraindication, is settled in the $88 evaluation with Dr. Kamen after your history, medications, and labs are reviewed.

Dr. Charles Kamen, MD decides whether a peptide belongs in a protocol after a medical evaluation. Results vary, and no specific outcome is guaranteed.

Peer-reviewed sources on Tesamorelin. Research does not constitute a treatment recommendation; appropriateness is determined only after a medical evaluation.

1. Falutz J, et al. N Engl J Med. 2007;357(23):2359-2370. (Tesamorelin reduces visceral fat in HIV lipodystrophy).